Drug Trial Radar · NCT03059823
A Phase 1 Study of INCMGA00012 in Patients With Advanced Solid Tumors
Last checked: Nov 20, 2026Latest source record: Aug 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
325
Actual
Start
Nov 15, 2016
Primary completion
May 22, 2024
Study completion May 22, 2024
Sponsor
- Lead sponsor
- Incyte CorporationIncyte (INCY)
- Sponsor type
- Industry
- First posted
- Feb 23, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary goal of this Phase 1 study is to characterize the safety and tolerability of INCMGA00012 and establish the maximum tolerated dose (MTD) of INCMGA00012 administered on either every two week or every four week schedules of administration among patients with solid tumors. Pharmacokinetics, pharmacodynamics, and the anti-tumor activity of INCMGA00012 will also be assessed. The purpose of Amendment 5 is to obtain additional safety experience at the newly defined recommended Phase 2 dose of 500 mg every 4 weeks in patients with endometrial cancer, specifically either microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR). Additionally, every 3 week (Q3W) flat-dosing will be studied in an additional tumor agnostic cohort.
Conditions
- Locally Advanced Solid Tumors
- Metastatic Solid Tumors
Interventions
retifanlimabDrug
Anti-PD-1 monoclonal antibody
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment-Emergent Adverse Events as assessed by CTCAE v4.03Time frame: 24 months
- MTDTime frame: 24 months
Locations
80 sites in 16 countries. Site status is shown where the registry gives one.
Honor Health Research Institute
Scottsdale, Arizona
South Texas Accelerated Research Therapeutics
Grand Rapids, Michigan
Rutgers Cancer Institute of Nj
New Brunswick, New Jersey
Carolina Bio-Oncology Institute, Pllc
Huntersville, North Carolina
Houston Methodist Hospital
Houston, Texas
University of Texas Md Anderson Cancer Center
Houston, Texas
South Texas Accelerated Research Therapeutics
San Antonio, Texas
Virginia Commonwealth University Massey Cancer Center
Richmond, Virginia
Chris Obrien Lifehouse
Camperdown, New South Wales, Australia
St Vincent'S Hospital Sydney
Darlinghurst, New South Wales, Australia
Universitair Ziekenhuis (Uz) Leuven
Leuven, Belgium
Centre Hospitalier Universitaire de Liege - Sart Tilman
Liège, Belgium
COMPLEX ONCOLOGY CENTER � BURGAS EOOD
Burgas, Bulgaria
Mc Women'S Health-Nadezhda Eood
Sofia, Bulgaria
Acibadem Cityclinica Mhat Tokuda
Sofia, Bulgaria
Umhat in Oncology
Sofia, Bulgaria
Peking Union Medical College Hospital
Beijing, China
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, China
Beijing Cancer Hospital
Beijing, China
Peking University Third Hospital
Beijing, China
Xiangya Hospital Central South University
Changsha, China
Hunan Cancer Hospital
Changsha, China
Sun Yat-Sen Memorial Hospital Sun Yat-Sen University
Guangzhou, China
The First Affiliated Hospital Sun Yat-Sen University
Guangzhou, China
Qilu Hospital of Shandong University
Jinan, China
Yunnan Cancer Hospital
Kunming, China
Zhongda Hospital Southeast University
Nanjing, China
The Fourth Hospital of Hebei Medical University
Shijiazhuang, China
The Second Hospital of Shanxi Medical University
Taiyuan, China
Tongji Hospital Huazhong University of Science and Technology
Wuhan, China
The First Affiliated Hospital of Xian Jiaotong University
Xi'an, China
The First Affiliated Hospital of Xiamen University
Xiamen, China
Henan Cancer Hostipal
Zhengzhou, China
Docrates Cancer Center
Helsinki, Finland
Turku University Hospital
Turku, Finland
Institut Bergonie
Bordeaux, France
Centre Leon Berard
Lyon, France
Centre Antoine Lacassagne
Nice, France
Hospital Universitaires de Geneve
Paris, France
Groupe Hospitalier Diaconesses Croix Saint-Simon
Paris, France
Showing 40 of 80 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.